Adenoviral targeting using genetically incorporated camelid single variable domains

Laboratory Investigation

Volumn 94, Issue 8, 2014, Pages 893-905

  Kaliberov, Sergey A ^a   Kaliberova, Lyudmila N ^a   Buggio, Maurizio ^a   Tremblay, Jacqueline M ^b   Shoemaker, Charles B ^b   Curiel, David T ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; EPITOPE; RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; ARTIODACTYLA; CANCER CELL LINE; CELL SPECIFICITY; CELL SURFACE; CHIMERA; CONTROLLED STUDY; DRUG PROTEIN BINDING; HEAVY CHAIN; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID;

ADENOVIRIDAE; ANIMALS; ANTIBODY SPECIFICITY; CAMELIDS, NEW WORLD; CAPSID PROTEINS; CARCINOEMBRYONIC ANTIGEN; CELL LINE; CELL LINE, TUMOR; FEASIBILITY STUDIES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MALE; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; VIRAL PROTEINS; VIRAL TROPISM; VIRION;

EID: 84905174041     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.82     Document Type: Article

References (52)

1. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25:462-466.
2. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002;1575:1-14.
3. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006;13: 830-844.
4. van Beusechem VW, Mastenbroek DC, van den Doel PB, et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther 2003;10:1982-1991.
5. Pereboev AV, Nagle JM, Shakhmatov MA, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004;9:712-720.
6. Li HJ, Everts M, Pereboeva L, et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007;67: 5354-5361.
7. Kim YS, Kim YJ, Lee JM, et al. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Hum Gene Ther 2010;21:1697-1706.
8. Beatty MS, Curiel DT. Chapter two-Adenovirus strategies for tissue-specific targeting. Adv Cancer Res 2012;115:39-67.
9. Hedley SJ, Auf der Maur A, Hohn S, et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2006;13:88-94.
10. Vellinga J, de Vrij J, Myhre S, et al. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther 2007;14:664-670.
11. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005;5:111-124.
12. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
13. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 2004;64: 2853-2857.
14. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-462.
15. Shao CY, Secombes CJ, Porter AJ. Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library. Mol Immunol 2007;44:656-665.
16. Wei G, Meng W, Guo H, et al. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One 2011;6:e28309.
17. Verheesen P, Roussis A, de Haard HJ, et al. Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation. Biochim Biophys Acta 2006;1764:1307-1319.
18. Goldman ER, Anderson GP, Liu JL, et al. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem 2006;78:8245-8255.
19. Reiter Y, Schuck P, Boyd LF, et al. An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J Mol Biol 1999;290:685-698.
20. Poulin KL, Lanthier RM, Smith AC, et al. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010;84:10074-10086.
21. Maass DR, Sepulveda J, Pernthaner A, et al. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods 2007;324:13-25.
22. Maass DR, Harrison GB, Grant WN, et al. Three surface antigens dominate the mucosal antibody response to gastrointestinal L3-stage strongylid nematodes in field immune sheep. Int J Parasitol 2007; 37:953-962.
23. Mukherjee J, Tremblay JM, Leysath CE, et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 2012;7:e29941.
24. Tremblay JM, Mukherjee J, Leysath CE, et al. A single VHH-based toxin neutralizing agent and an effector antibody protects mice against challenge with Shiga toxins 1 and 2. Infect Immun 2013;81:4592-4603.
25. Tremblay JM, Kuo CL, Abeijon C, et al. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 2010;56:990-998.
26. Robbins PF, Kantor JA, Salgaller M, et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991;51:3657-3662.
27. Belousova N, Korokhov N, Krendelshchikova V, et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 2003;77:11367-11377.
28. Behar G, Chames P, Teulon I, et al. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 2009;276:3881-3893.
29. Gottlin EB, Xiangrong G, Pegram C, et al. Isolation of novel EGFR-specific VHH domains. J Biomol Screen 2009;14:77-85.
30. Noureddini SC, Krendelshchikov A, Simonenko V, et al. Generation and selection of targeted adenoviruses embodying optimized vector properties. Virus Res 2006;116:185-195.
31. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95: 2509-2514.
32. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70:7498-7509.
33. Krasnykh VN, Mikheeva GV, Douglas JT, et al. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-6846.
34. Li HJ, Everts M, Yamamoto M, et al. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Res 2009;69:554-564.
35. Kaliberov SA, Kaliberova LN, Hong LuZ, et al. Retargeting of gene expression using endothelium specific hexon modified adenoviral vector. Virology 2013;447:312-325.
36. Santis G, Legrand V, Hong SS, et al. Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J Gen Virol 1999;80:1519-1527.
37. Shi ZR, Tsao D, Kim YS. Subcellular distribution, synthesis, and release of carcinoembryonic antigen in cultured human colon adenocarcinoma cell lines. Cancer Res 1983;43:4045-4049.
38. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338-351.
39. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138-143.
40. Ballesta AM, Molina R, Filella X, et al. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol 1995;16:32-41.
41. Kanetaka K, Ito S, Susumu S, et al. Clinical significance of carcinoembryonic antigen in peritoneal lavage from patients with gastric cancer. Surgery 2013;154:563-572.
42. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219:174-182.
43. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37: 272-277.
44. Huang A, Hindle KS, Tsavellas G. Colorectal cancer surveillance post-surgery. Hosp Med 2001;62:490-491.
45. Hareyama M, Imai K, Kubo K, et al. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer 1991;67:2269-2274.
46. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-7994.
47. Matsumoto H, Takahashi T, Mitsuhashi N, et al. Modification of tumor-associated antigen (CEA) expression of human lung cancer cells by irradiation, either alone or in combination with interferon-gamma. Anticancer Res 1999;19:307-311.
48. Matsui H, Sakurai F, Katayama K, et al. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein. Biomaterials 2013;34:4191-4201.
49. Whitlow M, Bell BA, Feng SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993;6:989-995.
50. Vigne E, Mahfouz I, Dedieu JF, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999;73:5156-5161.
51. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996;70:6831-6838.
52. Harmsen MM, Ruuls RC, Nijman IJ, et al. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol 2000;37:579-590.